Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus TOPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus TOPICORT.
COR-OTICIN vs TOPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
1-2 drops in each affected ear twice daily for 7 days.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal (metabolites): ~75%; Fecal: ~25%
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid